Sanket Koul

After cancer drugs, medtech firms seek uniform trade margin cap for devices

Domestic manufacturers want importers' margins included in a uniform trade margin framework for medical devices, with a pilot covering high-volume consumables such as IV sets

Centre to cap trade margins on non-scheduled cancer drugs at 30%

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

IPM volume growth at 3.4% marks 2-yr high on steady demand across therapies

Volume growth reached 3.5 per cent, the highest in two years, while pricing rose about 6.2 per cent as most therapy segments recorded stronger demand

State scrutiny of pharma price mark-ups may lead to review of TMR policy

Drug regulators in Maharashtra, Karnataka and Uttar Pradesh are gathering data on price mark-ups, potentially strengthening the case for a review of trade margin rationalisation

DLF completes sell-out in its senior living project for ₹1,985 crore

All 172 four-bedroom units at DLF's Aureva project in Gurugram were sold at an average ticket price of ₹11.5 crore, with NRIs accounting for 25 per cent of buyers

Affluent seniors are turning metros into luxury retirement addresses

Rising affluence, longer life expectancy and changing family structures are drawing mainstream developers to premium senior living projects in India's major urban markets

Drug regulator may review machinery disposal at non-compliant pharma units

The Drugs Consultative Committee has sought a detailed proposal from Rajasthan amid concerns that machinery from closed pharma units could be used to make spurious drugs

CDSCO seeks DGHS view on exemptions for mercury-based topical antiseptics

The Drugs Consultative Committee has sought the DGHS opinion and data on Merbromin's manufacture and use before deciding on its continued inclusion under Schedule K

Pharma dept to offer gap funding for early-stage novel drug discovery

Funding will be part of a new track under the PRIP scheme exclusively for start-ups and MSMEs at the initial research stage, with assistance of up to ₹50 crore per project

Following SC order on forensic audit, IHH may raise Fortis stake to 51%

IHH says India remains a key strategic market as it plans to deepen its Fortis investment, despite a Supreme Court-ordered forensic audit into past transactions

'This is carnage': SC flags high drug prices, moots 16% margin cap

A Bench of Justices Vikram Nath and Sandeep Mehta asked the Centre why the maximum retail price (MRP) of essential medicines such as cancer drugs could not be capped at 16 per cent

Supply constraints support premium office rents in Mumbai, Delhi-NCR

Consultants attribute premium rentals in key micro-markets to limited quality Grade A space and sustained occupier demand, even as rents vary significantly across locations

Medtech firms, hospitals back TMR amid medical device mark-up debate

Medtech manufacturers and private hospitals back trade margin rationalisation but seek a fact-based approach that accounts for category-specific costs and procurement structures

Embassy Reit gets ₹1,000 crore bank financing after RBI rule change

Trust becomes first Reit to access funding from a commercial bank after RBI allowed direct financing to Reits in June 2026

India's Ayush market could reach $213 billion by 2030: Primus Partners

Primus Partners says integrating Ayush into public health systems, insurance and primary care could help expand India's market to $213 billion by 2030 from $43 billion now

Accenture leases over 560,000 sq ft office space in Bengaluru for ₹269 cr

The five-year deal at Pritech Park SEZ includes renewal of an earlier lease for 441,000 sq ft and an additional 126,000 sq ft of office space

CDSCO flags indiscriminate use of painkillers, antibiotics over CKD risk

Drug regulator asks healthcare professionals and pharmacists to discourage indiscriminate use of NSAIDs and antibiotics, citing risks of kidney damage and CKD

Festive housing demand to stay healthy, but growth likely to moderate

Developers are becoming more calibrated in their launch strategies, while homebuyers are showing greater scrutiny around prices, payment terms and product quality

PB Health targets 150 hospitals, expansion into Tier-II, III cities

The venture aims to raise Rs 10,000 crore to build a network of 15,000-20,000 beds across more than 50 cities over the next five to six years

Gulshan Group, Ourika Estates form JV to invest ₹750 cr in UP projects

The platform has secured land parcels in Ghaziabad and Lucknow to develop about 1.5 million sq ft of built-up area across two premium residential projects